<unk>  is used in addition to other drugs to treat partial seizures and generalized tonic-clonic seizures for people older than twelve years. A 2016 review found it effective for both indications but due to the newness of the drug was unable to describe its optimal role in the treatment of epilepsy relative to other drugs. A 2014 review of the probability of added benefit of<unk>  to the standard of care was unable to come to any conclusions, as no trial conducted by Eisai compared<unk>  to a drug within the standard of care, but only to placebo.
Perampanel
Glybuzole
Glysobuzole
Methocarbamol
Tirapazamine
Milnacipran
Carbidopa
Tezacaftor